Protalix BioTherapeutics Reviewing Partnering and Other Alternatives
February 05 2013 - 11:43AM
Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX) (TASE:PLX),
confirms, in response to inquiries received this morning and a
report appearing in the Israeli press, that the company has engaged
Citigroup to assist it in reviewing a broad array of product
partnering, technology sharing and other strategic alternatives.
There is no assurance that Protalix will undertake any such
strategic alternative.
Protalix will not comment further on this initiative unless
future events would make doing so appropriate.
About Protalix
Protalix is a biopharmaceutical company focused on the
development and commercialization of recombinant therapeutic
proteins expressed through its proprietary plant cell based
expression system, ProCellEx®.
Forward-Looking Statements
To the extent that statements in this press release are not
strictly historical, all such statements are forward-looking, and
are made pursuant to the safe-harbor provisions of the Private
Securities Litigation Reform Act of 1995. The terms
"anticipate," "believe," "estimate," "expect" and "intend" and
other words or phrases of similar import are intended to identify
forward-looking statements. These forward-looking statements
are subject to known and unknown risks and uncertainties that may
cause actual future experience and results to differ materially
from the statements made. These statements are based on our
current beliefs and expectations as to such future
outcomes. Factors that might cause material differences
include, among others, risks relating to potential strategic
alternatives. The statements in this release are valid only as
of the date hereof and we disclaim any obligation to update this
information.
CONTACT: Investor Contact
Marcy Nanus
The Trout Group, LLC
646-378-2927
mnanus@troutgroup.com